CD274 and tuberculosis: Integrating pharmacovigilance data, MR, transcriptomic profiling, and structure-based drug discovery, we demonstrate that PD-L1 suppression, particularly via the checkpoint inhibitor durvalumab, may destabilize host-monocyte interactions critical for maintaining TB latency.